CNCR vs. AMOM

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and AMOM (QRAFT AI-Enhanced U.S. Large Cap Momentum ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while AMOM is a Momentum fund actively managed by Exchange Traded Concepts. CNCR is passively managed, while AMOM is actively managed. CNCR charges 0.79%/yr vs 0.75%/yr for AMOM.

Performance

CNCR vs. AMOM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

AMOM

• 1D: 1.65%
• 1M: 10.64%
• YTD: 26.64%
• 6M: 27.60%
• 1Y: 43.44%
• 3Y*: 27.79%
• 5Y*: 12.57%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. AMOM - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
AMOM QRAFT AI-Enhanced U.S. Large Cap Momentum ETF	20.54%

CNCR vs. AMOM - Sectors Allocation Comparison

Sectors	CNCR	AMOM
Healthcare	96.6%	7.7%
Financial Services	3.3%	6.2%
Basic Materials	-	2.7%
Communication Services	-	14.3%
Consumer Cyclical	-	5.8%
Consumer Defensive	-	5.0%
Energy	-	1.2%
Industrials	-	14.5%
Real Estate	-	1.9%
Technology	-	41.9%
Utilities	-	3.8%

Return for Risk

CNCR vs. AMOM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMOM

AMOM Risk / Return Rank: 61
AMOM Sharpe Ratio Rank: 59
AMOM Sortino Ratio Rank: 55
AMOM Omega Ratio Rank: 57
AMOM Calmar Ratio Rank: 67
AMOM Martin Ratio Rank: 66

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. AMOM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and QRAFT AI-Enhanced U.S. Large Cap Momentum ETF (AMOM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	AMOM	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.02	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.53	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.74	—

Drawdowns

CNCR vs. AMOM - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum AMOM drawdown of -39.68%. Use the drawdown chart below to compare losses from any high point for CNCR and AMOM.

Drawdown Indicators

	CNCR	AMOM	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-39.68%	+39.68%
Max Drawdown (1Y) Largest decline over 1 year	—	-13.10%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-30.26%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-39.68%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-10.82%	+10.82%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.64%	—

Volatility

Volatility by Period

	CNCR	AMOM	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.14%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.72%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	21.57%	-21.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	23.74%	-23.74%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	24.96%	-24.96%

CNCR vs. AMOM - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than AMOM's 0.75% expense ratio.

Dividends

CNCR vs. AMOM - Dividend Comparison

CNCR has not paid dividends to shareholders, while AMOM's dividend yield for the trailing twelve months is around 0.07%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
AMOM QRAFT AI-Enhanced U.S. Large Cap Momentum ETF	0.07%	0.09%	0.00%	0.47%	0.72%	0.74%	24.31%	5.51%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, CNCR or AMOM?

On fees, AMOM is cheaper at 0.75% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or AMOM?

AMOM is cheaper with a 0.75% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or AMOM?

AMOM has the higher dividend yield at 0.07%, compared with 0.00% for CNCR.

What is the main difference between CNCR and AMOM?

CNCR is categorized as Health & Biotech Equities, while AMOM is Momentum. Their fees differ too: 0.79% for CNCR and 0.75% for AMOM.